Compare Ascendis Pharma A/S (ASND) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Direxion Daily Semiconductor Bear 3X Shares trades at $4.45. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals.
| ASND | SOXS | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $160.60 |
52-Week Low | $163.32 | $3.25 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SOXS, the Direxion Daily Semiconductor Bear 3X Shares ETF, trades at $4.08 with minimal daily movement (+0.25%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The ETF is preparing for a 1:10 stock split effective July 15, 2026, and declared a $0.04 dividend for H1-2026. Recent news highlights the challenging environment for bearish semiconductor bets amid an ongoing AI-driven chip rally that has pressured inverse ETFs.
The outlook for SOXS remains highly speculative and risky, suitable only for sophisticated traders seeking short-term inverse exposure to semiconductors. The primary opportunity lies in potential semiconductor sector volatility or correction, while significant risks include continued AI-driven bullish momentum and the structural decay inherent in leveraged inverse ETFs during sustained market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
